As reported in The New England Journal of Medicine, findings in a phase II cohort of the multicohort KRYSTAL-1 phase I/II study indicated that the KRAS G12C inhibitor adagrasib showed activity in previously treated patients with unresectable or metastatic NSCLC and a KRAS G12C mutation.
